Wall Street impressed with initial prescriptions for Lilly's Foundayo Lilly cautions early weekly figures may not be fully comprehensive Demand for Novo Nordisk's oral Wegovy also strong April 17 ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The Eli Lilly logo appears on a laptop computer screen in this photo illustration in Athens, ...

Eli Lilly & Co.’s weight-loss pill won US approval, ratcheting up pressure on Novo Nordisk A/S, which launched an obesity pill earlier this year. Lilly’s once-daily pill, called Foundayo, was approved ...

Eli Lilly opposes the White House's push to codify 'most favored nation' drug pricing, Lilly CEO Dave Ricks said in an interview with CNBC. Lilly is one of more than a dozen pharmaceutical companies ...

The US Food and Drug Administration on Wednesday approved a new obesity pill called Foundayo. Taken once daily, the pill is made by pharmaceutical company Eli Lilly, which also manufactures the ...

Eli Lilly will pay up to $7.8 billion to acquire Centessa Pharmaceuticals. Centessa is developing orexin agonists to treat narcolepsy and excessive drowsiness. The deal is the latest from Lilly, which ...

Eli Lilly plans to acquire Centessa Pharmaceuticals, which has been conducting a midstage clinical trial of its lead drug. By Rebecca Robbins Eli Lilly reached a deal on Tuesday to buy Centessa ...

The US Supreme Court cleared the way for a multibillion-dollar racketeering lawsuit that accuses Takeda Pharmaceutical Co. and Eli Lilly & Co. of marketing the Actos diabetes drug without disclosing ...

Eli Lilly’s LLY-2.65%decrease; red down pointing triangle experimental weight-loss drug retatrutide met the primary and key secondary endpoints in a trial, showing significant improvements in weight ...

In a surprising move, Eli Lilly’s stock has been downgraded by HSBC analysts who argue that the heavily hyped weight-loss-drug market is due for a correction — and that the middle-class Americans who ...

Eli Lilly (LLY) shares slipped in the premarket on Tuesday after HSBC downgraded the weight loss drugmaker to Reduce from Hold, issuing the pharma giant’s only sell-equivalent rating on Wall Street, ...